Selected Publications

•Martinussen H, Reymen B, Wanders S, Troost EGC, Dingemans AMC, Öllers M, De Ruysscher D, Lambin P, van Baardwijk A. Risk of isolated nodal failure, treatment outcome and toxicity for stage III NSCLC treated with selective nodal irradiation using IMRT. Accepted for publication in Radiother Oncol.


•Eekers DBP , Roelofs E, Jelen U, Kirk M, Granzier M, Ammazzalorso F, Ahn P, Janssens GORJ, Hoebers FJP, Friedmann T, Solberg T, Troost EGC, Kaanders JHAM, Lambin P. Benefit of particle therapy in re-irradiation of Head and Neck patients. Results of a multicenter in silico ROCOCO trial. In press in Radiother Oncol.


•Wink KCJ, Belderbos JSA, Dieleman EMT, Rossi M, Rasch CRN, Damhuis RAM, Houben RMA, Troost EGC. Improved progression free survival for patients with diabetes and locally advanced non-small cell lung cancer (NSCLC) using metformin during concurrent chemoradiotherapy. Radiother Oncol 2016; 118:453-459.


•Jentsch C, Beuthien-Baumann B, Troost EGC, Shakirin G (2015) Validation of functional imaging results as a biomarker for radiation treatment response. Br J Radiol 88: 20150014.


•Troost EGC, Thorwarth D, Oyen WJG. Imaging-based treatment adaptation in radiation oncology. J Nucl Med 2015; 56(12):1922-1929.


•Grootjans W, de Geus-Oei L-F, Troost EGC, Visser EP, Oyen WJG, Bussink J. PET in the management of locally advanced and metastatic NSCLC. Nature Rev Clin Oncol 2015; 12:395-407.


•Zegers CML, Van Elmpt, W, Hoebers FJP, Troost EGC, Öllers MC, Mottaghy F, Lambin P. Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma. Acta Oncol 2015; 54(9):1378-1384.
•Even AJG, van der Stoep J, Zegers K, Reymen B, Lambin P, Troost EGC, van Elmpt W. PET-based dose painting in non-small cell lung cancer: comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes. Radiother Oncol 2015; 116(1):281-286.


•Trani D,  Yaromina A, Dubois L, Granzier M, Peeters S, Biemans R, Nalbantov G, Lieuwes N, Reniers B, Troost EGC, Verhaegen F, Lambin P. Pre-clinical assessment of efficacy of dose painting based on intratumoral FDG-PET uptake. Clin Cancer Research 2015; 21:5511-18.


•Zegers C, van Elmpt W, Reymen B, Even AJG, Troost EGC, Öllers M, Hoebers F, Windhorst A, Mottaghy F, de Ruysscher D, Lambin P. In vivo quantification of hypoxic and metabolic status of NSCLC using [18F]HX4 and [18F]FDG-PET/CT imaging. Clin Cancer Res 2014; 20(24):6389-97.


•Hoeben BAW*, Troost EGC*, van Herpen CM, Bussink J, Oyen WJG, Kaanders JHAM. 18FLT-PET is an early predictor of long-term outcome during (chemo)radiotherapy in head and neck cancer patients. J Nucl Med. 2013; 54(4):532-40; *shared first author.